Haleon Reports 3% Organic Growth in 2025 as 'Win as One' Strategy Drives Performance

Haleon delivered 3% organic growth in 2025, demonstrating resilience and strategic execution across its portfolio. The company reported consistent performance in key markets, with particular strength observed in its respiratory and pain relief categories. This outcome follows the company's implementation of the 'Win as One' strategy, aimed at enhancing operational efficiency, accelerating innovation, and improving supply chain agility. The 3% organic growth rate represents a measured but meaningful increase, underscoring the effectiveness of Haleon’s restructuring efforts. The company reported improved commercial execution, including stronger distribution coverage and elevated brand engagement, particularly in Europe and North America. Additionally, investments in digital marketing and e-commerce channels contributed to a 12% uplift in direct-to-consumer sales during the year. Haleon’s adjusted EBITDA margin reached 34.7% in 2025, up from 32.9% in the prior year, reflecting improved cost discipline and margin optimization. The company maintained its focus on high-growth therapeutic areas, with its global OTC (over-the-counter) portfolio delivering double-digit growth in emerging markets such as India, Brazil, and Indonesia. The results have bolstered investor confidence, with Haleon’s share price rising 5.3% in early trading following the release. Analysts noted the consistency of performance as a positive signal, especially given the broader challenges in the consumer health sector, including inflationary pressures and shifting consumer preferences.